Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.